Method for suppressing immune response associated with psoriasis, contact dermatitis and diabetes mellitus
AssigneeProcept, Inc.
InventorsDonard S. Dwyer, Kristin Esenther
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of Ruthenium Red as an immunosuppressive agent to prevent or significantly reduce graft rejection in organ and bone marrow transplantation. Ruthenium Red can also be used as an immunosuppressant drug for T lymphocyte mediated autoimmune diseases, such as diabetes. Furthermore, Ruthenium Red may be useful in alleviating psoriasis and contact dermatitis.
Claims9
A method for alleviating psoriasis and symptoms associated therewith resulting from a T-lymphocyte mediated immune response in a mammal comprising administering Ruthenium Red in a physiologically acceptable vehicle to an afflicted site on the mammal, thereby suppressing a T-lymphocyte mediated immune response associated with psoriasis.
A method for reducing hyperplasia of the epidermis resulting from a T-lymphocyte mediated immune response in a mammal caused by psoriasis comprising administering Ruthenium Red in a physiologically acceptable vehicle to an afflicted site on the mammal, thereby suppressing a T-lymphocyte mediated immune response associated with psoriasis.
A method for alleviating contact dermatitis and symptoms associated therewith resulting from a T-lymphocyte mediated immune response in a mammal comprising administering Ruthenium Red in a physiologically acceptable vehicle to an afflicted site on the mammal, thereby suppressing a T-lymphocyte mediated immune response associated with contact dermatitis.
Dependencies are inferred from the claim text.